CLDN18 and gastric cancer: The MONO trial enrolled patients with recurrent or refractory locally advanced or metastatic CLDN18.2 positive gastric (GC), adenocarcinoma of the oesophagogastric junction (GEJ) or oesophageal adenocarcinoma.